MAP2K1 and melanoma: In preclinical models of RAS mutant tumors, combination of a MEK inhibitor with autophagy inhibition using chloroquine or HCQ has demonstrated synergistic antitumor activity.3-5 Binimetinib, an orally bioavailable selective and potent mitogen-activated protein (MAP) kinase kinase (MEK1/2) inhibitor, was approved in 2018 by the US Food and Drug Administration (FDA) for treatment of patients with BRAF-mutant melanoma.